Viewsroom
Breakingviews columnists talk about the big numbers, crunchy deals and nasty spats in global business and economics, offering a weekly dose of financial insight that goes beyond the concise and provocative views readers get from our columns every day.
Latest Episode
No pain, no gain: Ozempic’s quest for market share (11.09.2025)
Previous Episodes
- France pushes EU’s omnicrisis to breaking point 04.09.2025
- Ukraine peace push stirs oil market limbo 14.08.2025
- Big law firms are at sharp end of AI boom 07.08.2025
- Japan’s M&A push faces internal obstacles 31.07.2025
- Wall Street bank boom is defying gravity 24.07.2025
- Trump’s tariff war demands countervailing force 17.07.2025
- Trump’s ‘beautiful’ bill leaves scars worldwide 10.07.2025
- Nippon Steel deal reveals cost of ‘America First’ 03.07.2025
- US IPO bounty may be tricky to duplicate 26.06.2025
- Israel-Iran crisis climbs ladder of financial risk 19.06.2025
- Elon Musk has a lot to lose in Trump brawl 12.06.2025
- AI arms race is only just getting started 05.06.2025
- Wild market swings are good reason to take stock 29.05.2025
- Gold glistens brighter in a chaotic world 22.05.2025
- Pauses, tweaks and can-kicking are new trade norms 15.05.2025
- Buffett’s $350 bln parting gift is double-edged 08.05.2025
- CK Hutchison deal is test of Chinese hospitality 01.05.2025
- The China-US trade war is set to keep spiraling 24.04.2025
- How Trump’s tariff turmoil scarred global markets 17.04.2025
- US tariff mania keeps everyone on edge 10.04.2025
